Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 94 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aspirin 325 mg Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aspirin Dose and Atherosclerosis in Patients With Heart Disease

NCT00272337
View directory record Official record
Conditions
Cardiovascular Diseases, Atherosclerosis, Myocardial Infarction
Interventions
Aspirin
Drug
Lead sponsor
Florida Atlantic University
Other
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
2
States / cities
Atlantis, Florida • Tamarac, Florida
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 3 Interventional

Warfarin Versus Aspirin Recurrent Stroke Study

NCT00027066
View directory record Official record
Conditions
Stroke
Interventions
Active Aspirin, Active Warfarin, Aspirin placebo, Warfarin placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
30 Years to 85 Years
Enrollment
2,206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients

NCT01823510
View directory record Official record
Conditions
Type-2 Diabetes Mellitus, Coronary Artery Disease
Interventions
Ticagrelor + Aspirin, Clopidogrel + Aspirin
Drug
Lead sponsor
Juan J Badimon
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

NCT01568112
View directory record Official record
Conditions
Healthy
Interventions
BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
25 Years to 55 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease

NCT01260584
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Prasugrel, Clopidogrel
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 74 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.

NCT05055752
View directory record Official record
Conditions
Bioequivalence
Interventions
Pharmaceutical-lipid aspirin (PL-ASA)
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

NCT00630877
View directory record Official record
Conditions
Dyslipidemia
Interventions
Niacin extended-release (NER), Niacin extended-release (NER) placebo, Aspirin (ASA), Aspirin (ASA) placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
40
States / cities
Birmingham, Alabama • Anaheim, California • Walnut Creek, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2009 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers

NCT01796951
View directory record Official record
Conditions
Tobacco Use Disorder, Smoking
Interventions
Aspirin 325 mg daily, Celecoxib 200 mg BID
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
35 Years to 90 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effects of Aspirin and Acetaminophen on the Stomach in Healthy Volunteers

NCT00594867
View directory record Official record
Conditions
Healthy
Interventions
Acetaminophen - 4 grams per day + Placebo, Aspirin - 325 mg per day + Placebo, Acetaminophen 4 gram per day + Aspirin 325 mg per day
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Alternate Dosing Regimens of BG00012 in Healthy Volunteers

NCT01281111
View directory record Official record
Conditions
Healthy
Interventions
Dimethyl Fumarate (BG00012), Aspirin, BG00012 matching placebo, ASA matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Evaluate Analgesic Efficacy of Fast Release Aspirin

NCT01122602
View directory record Official record
Conditions
Drugs, Investigational
Interventions
Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036), Acetylsalicyclic acid (Aspirin, BAYE4465), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
16 Years to 45 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Austin, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients

NCT01515657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PL2200 Aspirin Capsules, Immediate-Release Aspirin Tablets, Enteric-coated aspirin caplets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
21 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 25, 2026, 4:45 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Perioperative Bleeding and Aspirin Use in Spine Surgery

NCT02807441
View directory record Official record
Conditions
Hemorrhage, Thrombosis
Interventions
Acetylsalicylic acid
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

NCT01510327
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Loveland, Colorado • Petoskey, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 25, 2026, 4:45 PM EDT
Recruiting Phase 3 Interventional

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01355705
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Amrubicin, Lenalidomide, Dexamethasone, Aspirin, Pegfilgrastim
Drug
Lead sponsor
Michaela Liedtke
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 25, 2026, 4:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

NCT00790842
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Lenalidomide, Dexamethasone, Anticoagulants
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

NCT00687076
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA)
Drug · Behavioral · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
40 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches

NCT02176655
View directory record Official record
Conditions
Delayed Alcohol Induced Headache
Interventions
VVD-101, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
21 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Mountain View, California • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 25, 2026, 4:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Prostaglandins on Niacin-Induced Flushing

NCT00930839
View directory record Official record
Conditions
Flushing
Interventions
Niacin and aspirin
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
30 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Sep 25, 2026, 4:45 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

PFA 100 Evaluation and Reference Interval HOACNY

NCT06100510
View directory record Official record
Conditions
Effect of Drug
Interventions
Aspirin 325mg
Drug
Lead sponsor
Hematology Oncology Associates of Central New York
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Trial of Aspirin and Arginine Restriction in Colorectal Cancer

NCT00578721
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Aspirin
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 25, 2026, 4:45 PM EDT
Completed Phase 4 Interventional

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

NCT01239004
View directory record Official record
Conditions
Dyslipidemia, Hyperlipidemia, Hyperglycemia
Interventions
Placebo, Colesevelam
Drug
Lead sponsor
Radiant Research
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Sep 25, 2026, 4:45 PM EDT
Not listed Phase 2Phase 3 Interventional

Evaluation of the STARFlex® Septal Closure System in Patients With a Stroke or TIA Due to the Possible Passage of a Clot of Unknown Origin Through a Patent Foramen Ovale (PFO)

NCT00201461
View directory record Official record
Conditions
Patent Foramen Ovale, Stroke, Ischemic Attack, Transient
Interventions
STARFlex septal closure system, Best medical therapy
Device · Drug
Lead sponsor
NMT Medical
Industry
Eligibility
18 Years to 60 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2008 · Synced Sep 25, 2026, 4:45 PM EDT